Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

DIUTENSEN-R

METHYCLOTHIAZIDE; RESERPINE

Standard Dose
2.5MG;0.1MG
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued
Summary

Approval overview DIUTENSEN-R is listed in Drugs@FDA under application 012708 (NDA).

Marketing status: Discontinued Active ingredient METHYCLOTHIAZIDE; RESERPINE Form and strength TABLET;ORAL - 2.5MG;0.1MG Sponsor MEDPOINTE PHARM HLC Submission history Latest submission status date: 1975-09-30 00:00:00.

Structured Monograph

Clinical summary

Approval overview DIUTENSEN-R is listed in Drugs@FDA under application 012708 (NDA). Marketing status: Discontinued Active ingredient METHYCLOTHIAZIDE; RESERPINE Form and strength TABLET;ORAL - 2.5MG;0.1MG Sponsor MEDPOINTE PHARM HLC Submission history Latest submission status date: 1975-09-30 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued

Interaction Notes

  • No interaction notes stored yet.
DIUTENSEN-R (METHYCLOTHIAZIDE; RESERPINE) | Drug Monograph | MedicHelpline